Cullinan Therapeutics (CGEM) Change in Acquisitions & Divestments (2020 - 2026)

Cullinan Therapeutics' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $52.5 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 67.69% year-over-year to $52.5 million in Q1 2026; TTM through Mar 2026 was $306.5 million, a 49.19% decrease from a year earlier, with the FY2025 full-year figure at $416.6 million, down 28.77% from the prior year.
• Change in Acquisitions & Divestments climbed to $52.5 million in Q1 2026 per CGEM's latest filing, from $42.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $184.0 million in Q4 2024 and bottomed at $42.0 million in Q4 2025.
• The 5-year median for Change in Acquisitions & Divestments is $104.5 million (2023), against an average of $106.8 million.
• Across the five-year window, Change in Acquisitions & Divestments surged 662.08% in 2022 and sank 77.17% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $132.6 million in 2022, then declined by 11.4% to $117.5 million in 2023, then surged by 56.62% to $184.0 million in 2024, then sank by 77.17% to $42.0 million in 2025, then grew by 25.12% to $52.5 million in 2026.
• Per Business Quant, the three latest CGEM Change in Acquisitions & Divestments figures stand at $52.5 million (Q1 2026), $42.0 million (Q4 2025), and $80.0 million (Q3 2025).